GLP-1 Drug Composition & Weight Loss: Biomarker Context

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are medications containing active pharmaceutical ingredients—semaglutide, tirzepatide, or retatrutide—that mimic glucagon-like peptide-1, a natural hormone regulating appetite, blood sugar, and gastric emptying. Clinical trials show these medications can reduce body weight by 15–22% over 68 weeks, depending on formulation and dose.

Beyond understanding what's inside these medications, recognizing your individual metabolic context—including genetic predispositions in GLP-1 signaling pathways—can inform more personalized treatment discussions with your healthcare provider. PlexusDx emphasizes precision-wellness decision-making that combines pharmacological knowledge with biomarker insights.

Active Ingredients and Pharmacological Action in GLP-1 Medications

Three primary active ingredients dominate the GLP-1 market: semaglutide (a once-weekly injectable or daily oral), tirzepatide (a dual GLP-1/GIP receptor agonist, once-weekly), and retatrutide (a triple-hormone agonist in development). Each binds to the GLP-1 receptor with varying potency and selectivity, influencing both efficacy and side-effect profiles.

These ingredients slow gastric emptying, increase satiety signals to the brain, and enhance insulin secretion in response to meals. The molecular structure of each drug determines its half-life, tissue distribution, and onset of action—factors that shape real-world tolerability and weight-loss outcomes.

Comparative Composition: Injectable vs. Oral Formulations and Biomarker Considerations

Injectable and oral GLP-1 formulations differ in absorption kinetics, bioavailability, and patient adherence patterns. Compounded versions—semaglutide or tirzepatide from licensed 503A pharmacies—offer cost-accessible alternatives to branded options. Understanding your GLP-1 receptor genetic variants can help frame which formulation strategy your provider may recommend.

Formulation Type	Active Ingredient Examples	Dosing Schedule	Bioavailability Notes
Injectable (subcutaneous)	Semaglutide, Tirzepatide	Once weekly	Direct systemic absorption; predictable pharmacokinetics
Oral	Semaglutide, Tirzepatide	Daily	Requires fasting; lower bioavailability than injectable
Microdose protocol	Semaglutide or Tirzepatide	Flexible dosing	Lower starting doses; gradual titration for tolerability
Dual-compound (GLP-Squared)	Semaglutide + Tirzepatide	Varies by protocol	Combines GLP-1 and GIP signaling for enhanced response

Genetic Predispositions in GLP-1 Pathways and Treatment Response Context

Variations in genes encoding the GLP-1 receptor (GLP1R rs6923761), glucose-dependent insulinotropic polypeptide receptor (GIPR rs1800437), melanocortin-4 receptor (MC4R rs17782313), and fat-mass-and-obesity-associated gene (FTO rs9939609) influence how individuals respond to GLP-1 medications. These genetic predispositions do not determine outcomes but may provide context for provider discussions about dosing or formulation selection.

The Precision Peptide Genetic Test reveals your genetic profile across these peptide-pathway variants. This information should be interpreted with your qualified healthcare provider to inform a more personalized conversation—not as a predictor of exact medication response, but as one factor in a comprehensive assessment.

Safety Profile, Eligibility, and Who Should Consider GLP-1 Treatment

Common side effects include nausea, vomiting, diarrhea, and constipation, typically mild and dose-dependent. Rare serious adverse events include pancreatitis, gallbladder disease, and thyroid concerns. GLP-1 medications are contraindicated in personal or family history of medullary thyroid carcinoma and should be used cautiously in patients with type 1 diabetes or severe kidney disease.

Eligibility generally requires BMI ≥30 (or ≥27 with weight-related comorbidities) or diagnosis of type 2 diabetes. A comprehensive evaluation by your healthcare provider—including medical history, current medications, and any relevant biomarkers—ensures safe and effective use. PlexusDx recommends discussing your full clinical picture with your provider before initiating any GLP-1 medication.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for conversations about GLP-1 receptor agonist selection and dosing strategy. By identifying your genetic predispositions in key peptide-pathway genes, this test can support a more informed discussion with your healthcare provider about which formulation—injectable semaglutide, oral tirzepatide, or a microdose protocol—may align with your metabolic profile.

The genetic test reveals predispositions in GIPR, GLP1R, FTO, and MC4R variants—not as predictors of exact medication response, but as additional data points in your metabolic picture. These insights should always be interpreted by a qualified healthcare provider alongside your clinical history, current weight, comorbidities, and lifestyle factors.

Understanding what's inside GLP-1 medications, combined with awareness of your genetic context, enables a more nuanced conversation with your provider. This precision-wellness approach—grounded in both pharmacology and individual biology—supports collaborative decision-making about whether compounded semaglutide, tirzepatide, or a dual-compound option is most appropriate for your health journey.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.